Berberine Derivative Compound 13 as a Potent Promoter of Osteoblast Differentiation via Akt and PKC Signaling Pathways
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26072984 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Meiyu Piao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea. Hauptthemen laut MEDLINE: Osteoblasts, Proto-Oncogene Proteins c-akt, Berberine, Cell Differentiation. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wonkwang University, Wonkwang University in 2024.
Abstract (Originalsprache)
Berberine has been widely studied for its biological functions in various diseases, including cancer, diabetes, and cardiovascular diseases. Nevertheless, structural modifications of berberine have been demonstrated to augment its pharmacological efficacy in specific biological processes, particularly osteogenesis. In this study, we aimed to explore new berberine derivatives with pro-osteogenic activity and molecular mechanisms. Our results demonstrated that compound 13 is the most effective among the tested compounds. Compound 13 significantly enhanced BMP4-induced alkaline phosphatase (ALP) staining and increased the transcriptional activity of osteogenic markers such as ALP, Runt-related gene 2 (Runx2), and Osterix at both the mRNA and protein levels. Furthermore, we found that the Akt and PKC signaling pathways play crucial roles in compound 13-induced osteogenesis via treatment with specific inhibitors. The molecular docking results supported the potential interaction between compound 13 and these kinases. These findings highlighted the regulatory role of compound 13 in osteoblast differentiation via the Akt and PKC signaling pathways. Overall, our study provides compelling evidence that compound 13 is a promising therapeutic candidate for the treatment of osteoporosis, with the potential for further development and optimization to improve bone health and strength.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.
- Department of Oral Pharmacology, College of Dentistry, Wonkwang University, Iksan 54538, Republic of Korea.
ORCID-Profile: Meiyu Piao, Youn Ho Han
Förderung
- Wonkwang University
- Wonkwang University in 2024
Zitieren
APA
Piao, M., Han, Y. H., & Lee, K. Y. (2025). Berberine Derivative Compound 13 as a Potent Promoter of Osteoblast Differentiation via Akt and PKC Signaling Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072984
Vancouver
Piao M, Han YH, Lee KY. Berberine Derivative Compound 13 as a Potent Promoter of Osteoblast Differentiation via Akt and PKC Signaling Pathways. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072984
BibTeX
@article{Piao2025,
author = {Piao, Meiyu and Han, Youn Ho and Lee, Kwang Youl},
title = {Berberine Derivative Compound 13 as a Potent Promoter of Osteoblast Differentiation via Akt and PKC Signaling Pathways},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26072984}
}
EUVIMED